title: Response to Dr Bredemeier's letter.
authors.affiliation: National Institute of Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
authors.forename: Edward M
authors.initials: EM
authors.lastname: Vital
authors.forename: Shouvik
authors.initials: S
authors.lastname: Dass
authors.forename: Maya H
authors.initials: MH
authors.lastname: Buch
authors.forename: Andrew C
authors.initials: AC
authors.lastname: Rawstron
authors.forename: Paul
authors.initials: P
authors.lastname: Emery
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006801:Humans; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab
keywords: Adult Onset Still's Disease; Amyloidosis; Analgesics